Cardiovascular Burden of the V142I Transthyretin Variant
2024 · JAMA · 39 citations
https://doi.org/10.1001/jama.2024.4467
S
Senthil Selvaraj
Duke University(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
142
Papers
4.2K
Citations
29
h-index
56
i10-index
Senthil Selvaraj is an academic researcher from Duke University. The author has contributed to research in topics: Cardiovascular Function and Risk Factors & Diet and metabolism studies & Cardiac Imaging and Diagnostics. The author has an h-index of 29, co-authored 121 publications.
ORCID: 0000-0001-8418-7623Papers by this author
worksMetabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
2024 · Circulation Heart Failure · 21 citations
https://doi.org/10.1161/circheartfailure.124.011980
Towards Metabolomic-Based Precision Approaches for Classifying and Treating Heart Failure
2024 · JACC Basic to Translational Science · 19 citations
https://doi.org/10.1016/j.jacbts.2024.04.008
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction
2024 · JACC Heart Failure · 15 citations
https://doi.org/10.1016/j.jchf.2024.02.018
Metabolic and Pharmacokinetic Profiling of a Ketone Ester by Background SGLT2 Inhibitor Therapy in HFrEF
2024 · JACC Basic to Translational Science · 4 citations
https://doi.org/10.1016/j.jacbts.2024.10.014
Diagnostic Utility of SGLT2 Inhibitors to Facilitate Myocardial Glucose Suppression During Evaluation of Myocardial Inflammation
2024 · JACC. Cardiovascular imaging · 3 citations
https://doi.org/10.1016/j.jcmg.2024.02.011
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat